{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T06:28:13Z","timestamp":1793600893364,"version":"4.5.0"},"reference-count":42,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,2]],"date-time":"2026-04-02T00:00:00Z","timestamp":1775088000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100018217","name":"Universidade Federal de Sao Paulo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018217","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jad.2026.121721","type":"journal-article","created":{"date-parts":[[2026,3,31]],"date-time":"2026-03-31T15:24:01Z","timestamp":1774970641000},"page":"121721","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study"],"prefix":"10.1016","volume":"406","author":[{"given":"Jo\u00e3o Paulo","family":"Atidio","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo Simonini","family":"Delfino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor Saque","family":"Garios","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camila Serra Galdino Farias","family":"de Brito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuri Padilha","family":"Gerheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo Magalh\u00e3es","family":"de Almeida e Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodrigo","family":"Piloto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mateus Dadamos","family":"Ferro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rog\u00e9rio Onofre Pereira","family":"de Souza J\u00fanior","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana Canada","family":"Surjan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Acioly L.T.","family":"Lacerda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jad.2026.121721_bb0005","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.4088\/JCP.16l11277","article-title":"The antidepressant effect of repeat-dose intravenous ketamine is delayed by concurrent benzodiazepine use","volume":"78","author":"Albott","year":"2017","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0010","author":"Ashton"},{"issue":"6","key":"10.1016\/j.jad.2026.121721_bb0015","first-page":"403","article-title":"Treatment of major depressive disorder with benzodiazepines: a review","volume":"26","author":"Baldessarini","year":"2018","journal-title":"Harv. Rev. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.121721_bb0025","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1001\/jamapsychiatry.2017.3739","article-title":"Efficacy and safety of intranasal esketamine adjunctive to oral antidepressant therapy in treatment-resistant depression: a randomized clinical trial","volume":"75","author":"Daly","year":"2018","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0030","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.jad.2020.09.056","article-title":"Comparative effectiveness of esketamine in the treatment of anhedonia in bipolar and unipolar depression","volume":"278","author":"Delfino","year":"2021","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121721_bb0035","doi-asserted-by":"crossref","first-page":"1394787","DOI":"10.3389\/fpsyt.2024.1394787","article-title":"Facts and myths about use of esketamine for treatment-resistant depression: a narrative clinical review","volume":"15","author":"Di Vincenzo","year":"2024","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2026.121721_bb0040","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1126\/science.1222939","article-title":"Synaptic dysfunction in depression: potential therapeutic targets","volume":"338","author":"Duman","year":"2012","journal-title":"Science"},{"key":"10.1016\/j.jad.2026.121721_bb0045","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/nm.4050","article-title":"Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants","volume":"22","author":"Duman","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.jad.2026.121721_bb0050","series-title":"Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP), 14\u201317 October 2019","author":"EMA","year":"2019"},{"issue":"2","key":"10.1016\/j.jad.2026.121721_bb4005","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1176\/appi.ajp.161.2.217","article-title":"Long-term lithium therapy for bipolar disorder: systematic review and meta-analysis","volume":"161","author":"Geddes","year":"2004","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0055","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S0006-3223(03)00231-2","article-title":"Diagnosis and definition of treatment-resistant depression","volume":"53","author":"Fava","year":"2003","journal-title":"Biol. Psychiatry"},{"issue":"2","key":"10.1016\/j.jad.2026.121721_bb0060","doi-asserted-by":"crossref","first-page":"177","DOI":"10.4088\/JCP.08m04309","article-title":"A multidimensional tool to quantify treatment resistance in depression: the Maudsley staging method","volume":"70","author":"Fekadu","year":"2009","journal-title":"J. Clin. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0065","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.jad.2008.10.014","article-title":"What happens to patients with treatment-resistant depression? A systematic review of medium- to long-term outcome studies","volume":"116","author":"Fekadu","year":"2009","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2026.121721_bb0070","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1186\/s12888-018-1679-x","article-title":"Standardisation framework for the Maudsley staging method for treatment resistance in depression","volume":"18","author":"Fekadu","year":"2018","journal-title":"BMC Psychiatry"},{"issue":"3","key":"10.1016\/j.jad.2026.121721_bb0080","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1097\/JCP.0000000000000316","article-title":"Concomitant benzodiazepine use attenuates ketamine response: implications for large-scale study design and clinical development","volume":"35","author":"Frye","year":"2015","journal-title":"J. Clin. Psychopharmacol."},{"issue":"1","key":"10.1016\/j.jad.2026.121721_bb0085","doi-asserted-by":"crossref","first-page":"57","DOI":"10.3949\/ccjm.75.1.57","article-title":"The STAR*D study: treating depression in the real world","volume":"75","author":"Gaynes","year":"2008","journal-title":"Cleve. Clin. J. Med."},{"key":"10.1016\/j.jad.2026.121721_bb0090","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1177\/0269881109104845","article-title":"NMDA receptor antagonists augment antidepressant-like effects of lithium in the mouse forced swimming test","volume":"24","author":"Ghaemi","year":"2010","journal-title":"J. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121721_bb0095","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2020.172856","article-title":"Electrophysiological biomarkers of antidepressant response to ketamine in treatment-resistant depression","volume":"189","author":"Gilbert","year":"2020","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.jad.2026.121721_bb0100","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1017\/S0033291716000064","article-title":"Single-dose infusion ketamine and non-ketamine NMDA receptor antagonists for unipolar and bipolar depression: a meta-analysis","volume":"46","author":"Kishimoto","year":"2016","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2026.121721_bb0110","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s43440-020-00097-z","article-title":"Efficacy of single and repeated administration of ketamine in unipolar and bipolar depression: a meta-analysis of randomized clinical trials","volume":"72","author":"Kryst","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"10.1016\/j.jad.2026.121721_bb0115","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1001\/archpsyc.1994.03950030035004","article-title":"Subanesthetic effects of the NMDA antagonist ketamine in humans","volume":"51","author":"Krystal","year":"1994","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0120","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1097\/JCP.0000000000001475","article-title":"Association of optimal lamotrigine serum levels and therapeutic efficacy in mood disorders: a systematic review","volume":"41","author":"Kumar","year":"2021","journal-title":"J. Clin. Psychopharmacol."},{"issue":"5994","key":"10.1016\/j.jad.2026.121721_bb4010","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1126\/science.1190287","article-title":"MTOR-dependent synapse formation underlies the rapid antidepressant effects of NMDA antagonists","volume":"329","author":"Li","year":"2010","journal-title":"Science"},{"issue":"6","key":"10.1016\/j.jad.2026.121721_bb0125","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1192\/bjp.2023.79","article-title":"Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomized double-blind active-controlled trial","volume":"223","author":"Loo","year":"2023","journal-title":"Br. J. Psychiatry"},{"issue":"4","key":"10.1016\/j.jad.2026.121721_bb4015","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1111\/j.1600-0447.2005.00602.x","article-title":"Treatment-resistant depression: resistant or difficult to treat?","volume":"112","author":"Malhi","year":"2005","journal-title":"Acta Psychiatr. Scand."},{"key":"10.1016\/j.jad.2026.121721_bb0130","article-title":"Gender differences in suicidal and self-harming responses to esketamine: a real-world retrospective study","author":"Martiadis","year":"2025","journal-title":"Curr. Neuropharmacol."},{"key":"10.1016\/j.jad.2026.121721_bb0135","series-title":"Ketamine for Treatment-Resistant Depression: The First Decade of Progress","year":"2016"},{"key":"10.1016\/j.jad.2026.121721_bb0140","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1017\/S0033291714001603","article-title":"A systematic review and meta-analysis of randomized controlled trials of ketamine in major depressive episodes","volume":"45","author":"McGirr","year":"2015","journal-title":"Psychol. Med."},{"key":"10.1016\/j.jad.2026.121721_bb0150","first-page":"88","article-title":"CANMAT guidelines for the management of mood disorders","volume":"66","author":"McIntyre","year":"2021","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0155","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1007\/s11126-020-09830-6","article-title":"Effectiveness and safety of ketamine for unipolar depression: a systematic review","volume":"91","author":"Memon","year":"2020","journal-title":"Psychiatry Q."},{"issue":"8","key":"10.1016\/j.jad.2026.121721_bb4020","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1523\/JNEUROSCI.17-08-02921.1997","article-title":"Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to cortical excitation","volume":"17","author":"Moghaddam","year":"1997","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.jad.2026.121721_bb4025","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1192\/bjp.134.4.382","article-title":"A new depression scale designed to be sensitive to change","volume":"134","author":"Mongomery","year":"1979","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0160","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.19r12859","article-title":"Maintaining rapid antidepressant effects following ketamine infusion: a major unmet need","volume":"81","author":"Papakostas","year":"2020","journal-title":"J. Clin. Psychiatry"},{"issue":"6","key":"10.1016\/j.jad.2026.121721_bb4035","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1176\/appi.ajp.2019.19020172","article-title":"Efficacy and safety of the flexibly dosed esketamine nasal spray combined with a newly initiated oral antidepressant in treatment-resistant depression: a randomized double-blind active-controlled study","volume":"176","author":"Popova","year":"2019","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0165","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1176\/ajp.2006.163.11.1905","article-title":"Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report","volume":"163","author":"Rush","year":"2006","journal-title":"Am. J. Psychiatry"},{"issue":"Suppl 20","key":"10.1016\/j.jad.2026.121721_bb4040","first-page":"20","article-title":"The mini-international neuropsychiatric interview (M.I.N.I): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10","volume":"59","author":"Sheehan","year":"1998","journal-title":"J. Clin. Psychiatry"},{"issue":"5","key":"10.1016\/j.jad.2026.121721_bb0175","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1097\/JCP.0000000000001898","article-title":"Ketamine and esketamine for depression in daily practice: opportunities and challenges","volume":"44","author":"Singh","year":"2024","journal-title":"J. Clin. Psychopharmacol."},{"key":"10.1016\/j.jad.2026.121721_bb0180","first-page":"190","article-title":"Subcutaneous esketamine for suicidality in treatment-resistant depression","volume":"300","author":"Surjan","year":"2022","journal-title":"J. Affect. Disord."},{"issue":"2","key":"10.1016\/j.jad.2026.121721_bb0185","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1177\/0706743720970860","article-title":"CANMAT task force recommendations for the use of racemic ketamine in adults with major depressive disorder","volume":"66","author":"Swainson","year":"2021","journal-title":"Can. J. Psychiatry"},{"key":"10.1016\/j.jad.2026.121721_bb0190","first-page":"423","article-title":"Diazepam attenuates ketamine\u2019s antidepressant efficacy","volume":"210","author":"Torres-S\u00e1nchez","year":"2010","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2026.121721_bb0195","author":"U.S. Food and Drug Administration (FDA)"},{"key":"10.1016\/j.jad.2026.121721_bb0215","series-title":"Suicide rates","author":"World Health Organization","year":"2023"}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726005720?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032726005720?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T05:45:44Z","timestamp":1793598344000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032726005720"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":42,"alternative-id":["S0165032726005720"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2026.121721","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of concomitant benzodiazepines, lithium, and lamotrigine in modulating the antidepressant effects of subcutaneous esketamine in patients with treatment-resistant depressive episodes: A retrospective naturalistic study","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2026.121721","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"121721"}}